General Information

Mouse: (CB57BL/6J X CBA/ca) X Syn-/-CB57BL/6JOla

Expression of human C-terminal-truncated (1-120) wild type alpha-synuclein under the control of the rat tyrosine hydroxylase (TH) promoter.

Endogenous rat alpha synuclein: No (backcrossed to CB57BL/6JOla lacking alpha-synuclein)

Corresponding human genotype: Not reported but truncated alpha-synuclein is enriched in human Lewy body extracts

Transgene insertion:  not specified

References:  Tofaris 2006; Michell 2007

Transgene expression

  • 6 weeks – 14 months: High transgene expression is observed in SN and olfactory bulb. Protein expression is observed in the somatodendritic compartment of TH-positive neurons (SN) and in terminals (striatum). Truncated alpha-synuclein expression is also observed in the locus ceruleus.


  • Up to 14 months: No loss of TH-positive neurons is detected.

Dopamine Homeostasis

  • 1 months: No changes in striatal dopamine levels
  • 2-12 months: 30% reduction of dopamine and homovanillic acid levels are observed in the striatum


  • Up to 12 months: Inclusions positive for the truncated alpha-synuclein are observed in the olfactory bulb at all ages.
  • 12-14 months: perinuclear inclusion of truncated alpha-synuclein is observed in the SN.

Motor Behaviours

  • 6 months: No significant changes in total spontaneous activity are detected
  • 18 months: Reduced spontaneous activity is observed.

Response to L-DOPA treatment

  • Not reported

Non motor Behaviours

  • Not reported


  • Not reported


  • Up to 14 months: Progressive increase of inflammatory response is observed

Leave a Reply

Your email address will not be published. Required fields are marked *

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.